Live market news
Stocks
LEGB

LEGB

LEGBStock

Latest news on LEGBranked by Oyticker for market impact

72Impact
PositiveMajor information25 Sept 2026 · 11:00 UTC · Global · Medium term
Legend Biotech CARVYKTI Shows 50% Five-Year Progression-Free Survival in RRMM
Legend Biotech reported five-year data for CARVYKTI (ciltacabtagene autoleucel) in relapsed/refractory multiple myeloma (RRMM), with 50% of patients remaining progression-free and alive, and 69.2% overall five-year survival rate.
LEGBBiotechnologyOncologyCell & Gene Therapy

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on LEGBranked by Oyticker for market impact

Legend Biotech CARVYKTI Shows 50% Five-Year Progression-Free Survival in RRMM